scholarly journals Psychosocial and financial issues after hematopoietic cell transplantation

Hematology ◽  
2021 ◽  
Vol 2021 (1) ◽  
pp. 570-577
Author(s):  
David Buchbinder ◽  
Nandita Khera
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Psychosocial Care ◽  
Models Of Care ◽  
Hematopoietic Cell ◽  
Patient Centered ◽  
Center Staff ◽  
The Status ◽  
Centered Care ◽  
Improvement In Survival

Abstract With improvement in survival after hematopoietic cell transplantation (HCT), it has become important to focus on survivors' psychosocial issues in order to provide patient-centered care across the transplant continuum. The goals of this article are to describe updates in the literature on certain psychosocial domains (emotional/mental health and social/financial) in HCT survivors, offer a brief overview of the status of the screening and management of these complications, and identify opportunities for future practice and research. An evidence-based approach to psychosocial care can be broken down as primary (promoting health, raising awareness, and addressing risk factors), secondary (screening and directing early pharmacological and nonpharmacological interventions), and tertiary (rehabilitating, limiting disability, and improving quality of life) prevention. Implementing such an approach requires close coordination between multiple stakeholders, including transplant center staff, referring hematologist/oncologists, and other subspecialists in areas such as palliative medicine or psychiatry. Innovative models of care that leverage technology can bring these stakeholders together to fulfill unmet needs in this area by addressing barriers in the delivery of psychosocial care.

Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors

Hematology ◽  
2003 ◽  
Vol 2003 (1) ◽  
pp. 372-397 ◽  
Author(s):  
Rainer F. Storb ◽  
Guido Lucarelli ◽  
Peter A. McSweeney ◽  
Richard W. Childs
Keyword(s):  
Autoimmune Diseases ◽  
Aplastic Anemia ◽  
Solid Tumors ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Family Members ◽  
Hematopoietic Cell ◽  
Allogeneic Hct ◽  
The Status ◽  
Autologous Hct

Abstract Allogeneic hematopoietic cell transplantation (HCT) has been successfully used as replacement therapy for patients with aplastic anemia and hemoglobinopathies. Both autologous and allogeneic HCT following high-dose chemotherapy can correct manifestations of autoimmune diseases. The impressive allogeneic graft-versus-tumor effects seen in patients given HCT for hematological malignancies have stimulated trials of allogeneic immunotherapy in patients with otherwise refractory metastatic solid tumors. This session will update the status of HCT in the treatment of benign hematological diseases and solid tumors. In Section I, Dr. Rainer Storb reviews the development of nonmyeloablative conditioning for patients with severe aplastic anemia who have HLA-matched family members. He also describes the results in patients with aplastic anemia given HCT from unrelated donors after failure of responding to immunosuppressive therapy. The importance of leuko-poor and in vitro irradiated blood product transfusions for avoiding graft rejection will be discussed. In Section II, Dr. Guido Lucarelli reviews the status of marrow transplantation for thalassemia major and updates results obtained in children with class I and class II severity of thalassemia. He also describes results of new protocols for class III patients and efforts to extend HCT to thalassemic patients without HLA-matched family members. In Section III, Dr. Peter McSweeney reviews the current status of HCT for severe autoimmune diseases. He summarizes the results of autologous HCT for systemic sclerosis, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, and reviews the status of planned Phase III studies for autologous HCT for these diseases in North America and Europe. He also discusses a possible role of allogeneic HCT in the treatment of these diseases. In Section IV, Dr. Richard Childs discusses the development and application of nonmyeloablative HCT as allogeneic immunotherapy for treatment-refractory solid tumors. He reviews the results of pilot clinical trials demonstrating graft-versus-solid tumor effects in a variety of metastatic cancers and describes efforts to characterize the immune cell populations mediating these effects, as well as newer methods to target the donor immune system to the tumor.

scholarly journals Patient-centered care coordination in hematopoietic cell transplantation

2017 ◽  
Vol 1 (19) ◽  
pp. 1617-1627 ◽  
Author(s):  
Nandita Khera ◽  
Patricia Martin ◽  
Kristen Edsall ◽  
Anthony Bonagura ◽  
Linda J. Burns ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Care Coordination ◽  
Hematopoietic Cell Transplantation ◽  
Care Delivery ◽  
Treatment Options ◽  
Hematopoietic Cell ◽  
Coordinated Care ◽  
Patient Centered ◽  
Simplified Approach ◽  
Coordination Model

Abstract Hematopoietic cell transplantation (HCT) is an expensive, resource-intensive, and medically complicated modality for treatment of many hematologic disorders. A well-defined care coordination model through the continuum can help improve health care delivery for this high-cost, high-risk medical technology. In addition to the patients and their families, key stakeholders include not only the transplantation physicians and care teams (including subspecialists), but also hematologists/oncologists in private and academic-affiliated practices. Initial diagnosis and care, education regarding treatment options including HCT, timely referral to the transplantation center, and management of relapse and late medical or psychosocial complications after HCT are areas where the referring hematologists/oncologists play a significant role. Payers and advocacy and community organizations are additional stakeholders in this complex care continuum. In this article, we describe a care coordination framework for patients treated with HCT within the context of coordination issues in care delivery and stakeholders involved. We outline the challenges in implementing such a model and describe a simplified approach at the level of the individual practice or center. This article also highlights ongoing efforts from physicians, medical directors, payer representatives, and patient advocates to help raise awareness of and develop access to adequate tools and resources for the oncology community to deliver well-coordinated care to patients treated with HCT. Lastly, we set the stage for policy changes around appropriate reimbursement to cover all aspects of care coordination and generate successful buy-in from all stakeholders.

scholarly journals National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery

2015 ◽  
Vol 21 (7) ◽  
pp. 1308-1314 ◽  
Author(s):  
Navneet S. Majhail ◽  
Lih-Wen Mau ◽  
Pintip Chitphakdithai ◽  
Tammy Payton ◽  
Michael Eckrich ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
National Survey ◽  
Hematopoietic Cell Transplantation ◽  
Care Delivery ◽  
Models Of Care ◽  
Hematopoietic Cell ◽  
Transplantation Center

scholarly journals Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era

2015 ◽  
Vol 21 (1) ◽  
pp. 142-150 ◽  
Author(s):  
Navneet S. Majhail ◽  
Pintip Chitphakdithai ◽  
Brent Logan ◽  
Roberta King ◽  
Steven Devine ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Unrelated Donor ◽  
Improvement In Survival

Metacommunication process during a 3-day digital storytelling workshop for patients recovering from hematopoietic cell transplantation

2020 ◽  
Vol 30 (2) ◽  
Keyword(s):  
Cell Transplantation ◽  
Digital Storytelling ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Constructivist Grounded Theory ◽  
Cancer Center ◽  
Theory Approach ◽  
Patient Centered ◽  
Team Members ◽  
Phoenix Metropolitan Area

Abstract Purpose: The purpose of this study was to qualitatively analyze metacommunication during the digital storytelling (DST) workshop process for patients undergoing hematopoietic cell transplantation (HCT). Methods: HCT survivors who had undergone transplant within the past 2 years were recruited at a cancer center in the Phoenix Metropolitan area. Participants (M age = 51.5 years) attended a 3-day DST workshop telling and creating digital stories around their HCT experiences. Using a constructivist grounded theory approach, line by line coding and content analysis were conducted with four research team members. Results: Four themes emerged from the data: (1) communal connection; (2) expressing and processing emotions; (3) self-empowerment; and (4) multi-dimensional coping. Participants described telling and sharing their story with other HCT patients as therapeutic. Conclusion: DST shows promise as a potential coping tool and offers multiple dimensions of the role of narrative as a coping technique, in community building, and in patient-centered contexts within HCT.

Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors

Hematology ◽  
2003 ◽  
Vol 2003 (1) ◽  
pp. 372-397 ◽  
Author(s):  
Rainer F. Storb ◽  
Guido Lucarelli ◽  
Peter A. McSweeney ◽  
Richard W. Childs
Keyword(s):  
Autoimmune Diseases ◽  
Aplastic Anemia ◽  
Solid Tumors ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Family Members ◽  
Hematopoietic Cell ◽  
Allogeneic Hct ◽  
The Status ◽  
Autologous Hct

Allogeneic hematopoietic cell transplantation (HCT) has been successfully used as replacement therapy for patients with aplastic anemia and hemoglobinopathies. Both autologous and allogeneic HCT following high-dose chemotherapy can correct manifestations of autoimmune diseases. The impressive allogeneic graft-versus-tumor effects seen in patients given HCT for hematological malignancies have stimulated trials of allogeneic immunotherapy in patients with otherwise refractory metastatic solid tumors. This session will update the status of HCT in the treatment of benign hematological diseases and solid tumors. In Section I, Dr. Rainer Storb reviews the development of nonmyeloablative conditioning for patients with severe aplastic anemia who have HLA-matched family members. He also describes the results in patients with aplastic anemia given HCT from unrelated donors after failure of responding to immunosuppressive therapy. The importance of leuko-poor and in vitro irradiated blood product transfusions for avoiding graft rejection will be discussed. In Section II, Dr. Guido Lucarelli reviews the status of marrow transplantation for thalassemia major and updates results obtained in children with class I and class II severity of thalassemia. He also describes results of new protocols for class III patients and efforts to extend HCT to thalassemic patients without HLA-matched family members. In Section III, Dr. Peter McSweeney reviews the current status of HCT for severe autoimmune diseases. He summarizes the results of autologous HCT for systemic sclerosis, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, and reviews the status of planned Phase III studies for autologous HCT for these diseases in North America and Europe. He also discusses a possible role of allogeneic HCT in the treatment of these diseases. In Section IV, Dr. Richard Childs discusses the development and application of nonmyeloablative HCT as allogeneic immunotherapy for treatment-refractory solid tumors. He reviews the results of pilot clinical trials demonstrating graft-versus-solid tumor effects in a variety of metastatic cancers and describes efforts to characterize the immune cell populations mediating these effects, as well as newer methods to target the donor immune system to the tumor.

Sign in / Sign up

Export Citation Format

Share Document